• KOL
    • Multiple Myeloma
    • Kenneth Carl Anderson
    • Kenneth Carl Anderson: Influence Statistics

      Kenneth Carl Anderson

      Kenneth Carl Anderson

      Show email address

      Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, 02215, Boston, MA, USA | Department of Medical Oncology, Dana-Farber ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Kenneth Carl Anderson:Expert Impact

      Concepts for whichKenneth Carl Andersonhas direct influence:Multiple myeloma,Mm cells,Bone marrow,Myeloma cells,Multiple myeloma mm,Multiple myeloma cells,Mm cell,Tumor cells.

      Kenneth Carl Anderson:KOL impact

      Concepts related to the work of other authors for whichfor which Kenneth Carl Anderson has influence:Multiple myeloma,Bone marrow,Cancer cells,Stem cell,Proteasome inhibitors,Gene expression,Monoclonal antibodies.

      KOL Resume for Kenneth Carl Anderson

      Year
      2022

      Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, 02215, Boston, MA, USA

      Harvard Medical School, United States

      2021

      Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA USA

      Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

      Dana-Farber Cancer Institute, Boston, Massachusetts, United States

      2020

      Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA

      Department of Medical Oncology, Harvard Medical School, Boston, MA;

      2019

      Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

      Department of Medical Oncology, Dana‐Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts

      LeBow Institute for Myeloma Therapeutics and

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Kenneth Carl Anderson is among the top experts in the world.
      Concept World rank
      bortezomib cell #1
      pgp bortezomib resistance #1
      wbc storage #1
      treatment multiple #1
      tabalumab bortezomib #1
      cdis phosphorylation #1
      wt161 hdac6 inhibition #1
      primary mm #1
      resistance improve #1
      bmscs adhesion #1
      overcomes bortezomib resistance #1
      mm cell death #1
      cd20 mm #1
      signaling mm #1
      lenalidomide trigger #1
      therapies including #1
      mm cell viability #1
      dexresistance #1
      secretion mm #1
      cells multiple #1
      activation multiple #1
      catabolic kynurenine #1
      exclusive transfusion #1
      hun901dm1 #1
      patient mm #1
      antimm immunity #1
      xmab5592 #1
      apoptosis drug resistance #1
      bortezomib addition #1
      bortezomib dexamethasone bortezomib #1
      pis multiple myeloma #1
      specific xbp1 #1
      apoptotic sensitivity #1
      relapse rvd #1
      liposomal carfilzomib #1
      mm cells perifosine #1
      outcome eventual cure #1
      tumor cells antigens #1
      bortezomib mm #1
      mpctls #1
      kinases multiple #1
      pyrazines tumor cells #1
      trail mm cells #1
      antimm activities #1
      pdcs mm #1
      imids cytokine #1
      caspase8 caspase9 #1
      including multiple #1
      il6 dex #1
      mm healthy donors #1
      Sign-in to see all concepts, it's free!

      Prominent publications by Kenneth Carl Anderson

      KOL-Index: 26546

      BACKGROUND: As lenalidomide becomes increasingly established for upfront treatment of multiple myeloma, patients refractory to this drug represent a population with an unmet need. The combination of pomalidomide, bortezomib, and dexamethasone has shown promising results in phase 1/2 trials of patients with relapsed or refractory multiple myeloma. We aimed to assess the efficacy and safety of this triplet regimen in patients with relapsed or refractory multiple myeloma who previously ...

      Known for Dexamethasone Patients | Multiple Myeloma | Pomalidomide Bortezomib | Phase 3 | Received Lenalidomide
      KOL-Index: 25909

      BACKGROUND: Isatuximab is a monoclonal antibody that binds a specific epitope on the human CD38 receptor and has antitumour activity via multiple mechanisms of action. In a previous phase 1b study, around 65% of patients with relapsed and refractory multiple myeloma achieved an overall response with a combination of isatuximab with pomalidomide and low-dose dexamethasone. The aim of this study was to determine the progression-free survival benefit of isatuximab plus pomalidomide and ...

      Known for 3 Study | Pomalidomide Dexamethasone | Refractory Multiple | Patients Isatuximab | Monoclonal Antibodies
      KOL-Index: 25259

      Increased angiogenesis has recently been recognized in active multiple myeloma (MM). Since vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) are two key mediators of angiogenesis, we characterized the production of VEGF, b-FGF and interleukin-6 (IL-6) (a MM growth and survival factor) in MM cell lines and Epstein–Barr virus (EBV) transformed B cell lines from MM patients, patient MM cells, as well as bone marrow stromal cells (BMSCs) from normal healthy ...

      Known for Mm Cells Bmscs | Growth Factor | Vascular Endothelial | Stromal Cells | Il6 Vegf
      KOL-Index: 23159

      BACKGROUND: Multiple myeloma is an incurable haematological malignancy, representing over 10% of haematological cancers in the USA. We did a phase 1-2 study of melflufen and dexamethasone in patients with relapsed and refractory multiple myeloma to determine the maximum tolerated dose of melflufen and to investigate its safety and efficacy.

      METHODS: We did a multicentre, international, dose-confirmation and dose-expansion, open-label, phase 1-2 study in seven centres in the USA and ...

      Known for Multiple Myeloma | Melflufen Patients | Combination Dexamethasone | Single Agent | Phase 2
      KOL-Index: 22815

      BACKGROUND: Bortezomib, lenalidomide, and dexamethasone (VRd) is a standard therapy for newly diagnosed multiple myeloma. Carfilzomib, a next-generation proteasome inhibitor, in combination with lenalidomide and dexamethasone (KRd), has shown promising efficacy in phase 2 trials and might improve outcomes compared with VRd. We aimed to assess whether the KRd regimen is superior to the VRd regimen in the treatment of newly diagnosed multiple myeloma in patients who were not being ...

      Known for Patients Vrd | Diagnosed Multiple | Induction Therapy | Lenalidomide Dexamethasone | Phase 3
      KOL-Index: 21272

      Donor lymphocyte infusions (DLI) can induce remissions in patients who have relapsed after allogeneic bone marrow transplantation (BMT). However, DLI frequently also result in significant acute and/or chronic graft-versus-host disease (GVHD). Several clinical and experimental lines of evidence have suggested that CD8(+) T cells play a critical role in the pathogenesis of GVHD. To develop methods to reduce the incidence of GVHD associated with DLI, we administered defined numbers of ...

      Known for Gvhd Patients | Donor Lymphocytes | Bone Marrow | Allogeneic Bmt | Cd4 Dli
      KOL-Index: 20807

      BACKGROUND: During the storage of cellular components before transfusion, cytokines that may mediate transfusion reactions are released from white cells (WBCs). Adverse effects of transfused cellular blood components therefore depend not only on the number of residual WBCs in blood components, but also on the timing of WBC reduction.

      STUDY DESIGN AND METHODS: Febrile nonhemolytic transfusion reactions (FNHTRs), allergic reactions, and other reactions were characterized in recipients of ...

      Known for Blood Components | Transfusion Rbcs | White Cell | Allergic Reactions | Wbc Reduced
      KOL-Index: 18770

      In multiple myeloma (MM), migration is necessary for the homing of tumor cells to bone marrow (BM), for expansion within the BM microenvironment, and for egress into the peripheral blood. In the present study we characterize the role of vascular endothelial growth factor (VEGF) and beta(1) integrin (CD29) in MM cell migration. We show that protein kinase C (PKC) alpha is translocated to the plasma membrane and activated by adhesion of MM cells to fibronectin and VEGF. We identify beta(1) ...

      Known for Endothelial Growth | Protein Kinase | Multiple Myeloma | Phosphatidylinositol 3 | Pkc Alpha
      KOL-Index: 17894

      Smac, second mitochondria-derived activator of caspases, promotes apoptosis via activation of caspases. Previous studies have shown that c-Jun NH(2)-terminal kinase (JNK) is involved in regulating another mitochondrial protein, cytochrome c during apoptosis; however, the role of JNK in the release of mitochondrial Smac is unknown. Here we show that induction of apoptosis in multiple myeloma (MM) cells is associated with activation of JNK, translocation of JNK from cytosol to ...

      Known for Mitochondrial Protein | Jnk Smac | Apoptosis Activation | Mitochondria Release | Multiple Myeloma
      KOL-Index: 17876

      PURPOSE: Aurora kinases, whose expression is linked to genetic instability and cellular proliferation, are being investigated as novel therapeutic targets in multiple myeloma (MM). In this study, we investigated the preclinical activity of a small-molecule multitargeted kinase inhibitor, AT9283, with potent activity against Aurora kinase A, Aurora kinase B, and Janus kinase 2/3.

      EXPERIMENTAL DESIGN: We evaluated the in vitro antimyeloma activity of AT9283 alone and in combination with ...

      Known for Aurora Kinase | Mm Cells | Antimyeloma Activity | Multiple Myeloma | Benzimidazoles Cell
      KOL-Index: 17575

      Interleukin-6 (IL-6) is a growth factor for multiple myeloma (MM) cells and can inhibit MM cell apoptosis. Our recent studies show that IL-6 facilitates MM cell growth via phosphorylation of retinoblastoma protein (pRB); however, the effects of IL-6 on those cyclins, cyclin-dependent kinases (CDKs), and CDK inhibitors (CDIs) that are known to regulate phosphorylation of pRB have not been defined in MM cells. In the present report, we cultured MM cell lines and patient cells with IL-6 ...

      Known for Mm Cells | G1 Growth Arrest | Dex Il6 | Multiple Myeloma | P21waf1 Upregulation

      Key People For Multiple Myeloma

      Top KOLs in the world
      #1
      Kenneth Carl Anderson
      multiple myeloma mm cells board directors
      #2
      Robert A Kyle
      multiple myeloma undetermined significance consultancy funding
      #3
      Sundararajan Vincent Rajkumar
      multiple myeloma consultancy funding undetermined significance
      #4
      Paul Gerard Guy Richardson
      multiple myeloma board directors advisory committees
      #5
      JesusFernando San San Miguel
      multiple myeloma consultancy honoraria board directors
      #6
      Bart Barlogie
      multiple myeloma total therapy gene expression

      Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, 02215, Boston, MA, USA | Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Center for Multiple Myeloma Research, Harvard Me

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.